← All trials
NCT04759365
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 2, 2021
- Primary completion
- Jan 31, 2022
- Completion date
- Jan 31, 2022
- First posted
- Feb 18, 2021
- Last posted
- Jul 23, 2021
- Enrollment
- 76
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Asceneuron Pty Ltd.Lead sponsor
- Neuroscience Trials AustraliaCollaborator
- Asceneuron S.A.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.